Estimation of the efficiency of allergen-specific immunotherapy in patients with atopic asthma and allergic rhinitis

2019 ◽  
Vol 17 (6 (part 1)) ◽  
pp. 44-48
Author(s):  
O. V. Skorokhodkina ◽  
◽  
A. V. Luntsov ◽  
S. A. Arkhipova ◽  
◽  
...  
2016 ◽  
Vol 97 (2) ◽  
pp. 288-294
Author(s):  
N M Rakhmatullina ◽  
Yu V Pastushenko ◽  
O R Trofimova ◽  
N A Sibgatullina ◽  
D G Akhmedzyanova ◽  
...  

The article presents the modern methods of allergen-specific immunotherapy in patients with allergic rhinitis. Allergen-specific immunotherapy - a method of treating allergic diseases, involves reducing the organism’s sensitivity to the allergen effects by repeated administration of allergen extract, starting with the minimum dose. Given the allergic rhinitis high prevalence, as well as its tendency to increase, strong interest in effective methods of its treatment is fully justified. Over the last 20 years, it has become clear that asthma and rhinitis are two types of manifestations of a single pathological process in the airways. It has been proven that allergic disease clinical features may change over time. In addition, patients with allergy are prone to multivalent sensitization. Currently none of the drugs used to relieve allergic rhinitis symptoms can not change the organism’s response to an allergen. Allergen-specific immunotherapy can reduce allergic disease symptoms severity, reduces the need in drugs use, decreases the chance of additional sensitization to other allergens, prevents the asthma development. This therapy has become one of the most widely used effective methods of atopic diseases treatment: seasonal and perennial rhinoconjunctivitis, atopic asthma. Allergen-specific immunotherapy can lead to a change in the immunological response to the relevant allergens in early stages, acting through regulatory cells. Current studies are aimed, on the one hand, at reducing the therapeutic allergovaccines ability to cause allergic reactions, on the other - to maintain or enhance their immunogenic properties. Achieving this goal is possible by changing the route of administration and delivery of therapeutic allergens (non-injection methods of allergen-specific immunotherapy), and using a variety of allergens modification techniques.


2015 ◽  
Vol 12 (6) ◽  
pp. 54-67
Author(s):  
N M Nenasheva

Bronchial asthma is a heterogeneous disease in terms of the phenotypes, but the majority of patients, both children and adolescents, and adults suffer from IgE-dependent (atopic) asthma. This asthma phenotype most often is associated with allergic rhinitis, which defines systemic therapy for both diseases. The allergen-specific immunotherapy (SIT) meets that approach best of all. SIT is viewed as a treatment not for a specific nosology (rhinitis, asthma or atopic dermatitis), but for an allergen. The epidemiology and the etiology of atopic asthma, role of SIT in treatment of asthma, efficacy, safety, and basic mechanisms are discussed in the article.


2021 ◽  
Vol 30 (1) ◽  
pp. 175-181
Author(s):  
Lobna A. El-Korashi ◽  
Ola E. Nafea ◽  
Lamiaa G. Zake ◽  
Faika Arab ◽  
Reham H. Anis

Background: 1, 25-dihydroxy vitamin D3 (VitD3) can improve the effect of allergenspecific immunotherapy (SIT). Few data is available about its role in childhood asthma. Objective: To assess the immunological and clinical efficacy of VitD3 as an adjuvant to allergen specific immunotherapy in pediatric asthma. Methodology: Sixty nine children with atopic asthma were divided into three groups: a group received subcutaneous immunotherapy (SCIT) in combination with VitD3 (n=23), another group received SCIT alone (n=23), and the last group VitD3 alone (n=23). All children were assessed at baseline, and six months for rate of inhaled corticosteroid (ICS) discontinuation, and serum levels of IL-10, and IL-17A. Results: In the SCIT + vitD3, ICS discontinuation rate was higher compared to VitD3 alone group and SCIT alone group at the end of 6th month (P=0.555 and 0.016 respectively). The combined SCIT+ VitD3 group showed significant increase of serum IL-10 level in comparison to SCIT alone group and VitD3 alone group (P=0.000) and significant decrease in serum IL-17A level compared to VitD3 alone group (P= 0.011) Conclusion: VitD3 enhance the clinical and immunological outcomes of SIT in pediatric asthma. Further investigation is needed to evaluate this effect in a larger scale to confirm its role as an adjunct to SIT.


2011 ◽  
Vol 22 (1) ◽  
pp. 15-23 ◽  
Author(s):  
Cengiz Kirmaz ◽  
Ozlem Ozenturk Kirgiz ◽  
Papatya Bayrak ◽  
Ozge Yilmaz ◽  
Seda Vatansever ◽  
...  

2017 ◽  
Vol 131 (11) ◽  
pp. 997-1001 ◽  
Author(s):  
E Sahin ◽  
D Dizdar ◽  
M E Dinc ◽  
A A Cirik

AbstractBackground:Allergic rhinitis is strongly associated with the presence of house dust mites. This study investigated the long-term effects of allergen-specific immunotherapy. Allergen-specific immunotherapy was applied over three years. The study was based on a 10-year follow up of patients with allergic rhinitis.Methods:The study was conducted between 2001 and 2015. Skin prick test results and symptom scores were evaluated before (26 patients) and after 3 years (20 patients) of allergen-specific immunotherapy (using data from a previously published study), and 10 years after allergen-specific immunotherapy had ended (20 of 26 patients).Results:The symptom scores before allergen-specific immunotherapy were significantly higher than those obtained after 3 years of allergen-specific immunotherapy and 10 years after allergen-specific immunotherapy (p < 0.0175). There were no significant differences between the scores obtained at 3 years and 10 years after allergen-specific immunotherapy (p > 0.0175).Conclusion:Subcutaneous immunotherapy is an effective treatment for house dust mite induced allergic rhinitis.


Allergy ◽  
2010 ◽  
Vol 65 (12) ◽  
pp. 1525-1530 ◽  
Author(s):  
T. Zuberbier ◽  
C. Bachert ◽  
P. J. Bousquet ◽  
G. Passalacqua ◽  
G. Walter Canonica ◽  
...  

2016 ◽  
Vol 8 (2) ◽  
pp. 132 ◽  
Author(s):  
Xi Luo ◽  
Haiyu Hong ◽  
Jun Tang ◽  
Xingmei Wu ◽  
Zhibin Lin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document